ReNeuron raises £3M for neural foetal stem cell trial

Placing

Stem cell specialist ReNeuron Group plc is aiming to raise up to £3 million via a placing of up to 100 million new shares, providing the hard-up company with sufficient working capital for at least the next 12 months.

The money will fund the Phase I trial of ReN001, ReNeuron’s foetal neural stem cell product, in the treatment of stroke. The trial was approved by UK regulators in January.